Promising effects of blocking CTGF by pamrevlumab has been shown in rats and in earlier studies in patients with lung fibrosis (Wang et al. 2011; Bickelhaupt et al. 2017; Cui et al. 2018; Richeldi et al. 2020). The gene discussed is CCN2; the disease is pulmonary fibrosis.